OncoMed Pharmaceuticals, Inc. previously announced that rosmantuzumab (anti-RSPO3, OMP-131R10) had failed to provide compelling evidence of clinical benefit in a Phase 1a/b clinical trial in patients with solid tumors and that the Company was discussing next steps for the program with its partner Celgene Corporation (“Celgene”). On October 15, 2018, Celgene notified the Company of its decision not to exercise its option to license rosmantuzumab and subsequently terminated the companies’ collaboration agreement with respect to rosmantuzumab, effective February 12, 2019. The Company will retain worldwide rights to rosmantuzumab upon termination. Celgene continues to retain its option under the collaboration agreement to license etigilimab (anti-TIGIT, OMP-313M32).